The global companion diagnostics market size was valued at USD 8.98 billion in 2025 and is projected to grow from USD 10.09 billion in 2026 to USD 25.57 billion by 2034, registering a CAGR of 12.33% during the forecast period from 2026 to 2034. North America dominated the companion diagnostics market with a market share of 42.5% in 2025.
Companion diagnostics are medical tests used to identify patients who are most likely to benefit from, or experience risks from, a specific therapeutic treatment. They analyze biomarkers such as genes, proteins, or other biological characteristics to support personalized treatment decisions. Companion diagnostics are widely used in oncology and other therapeutic areas to improve treatment effectiveness, reduce adverse reactions, and enable more precise patient care.
Download a Free Sample To learn more about this report,
Growing Adoption of Biomarker-Based Testing for Targeted Therapies
The companion diagnostics market trends are increasingly shaped by precision medicine, where molecular tests help doctors identify patients most likely to benefit from a particular treatment. Pharmaceutical and diagnostic companies are developing tests that detect biomarkers such as genetic mutations, protein expression, and other molecular characteristics before or during treatment. The U.S. FDA maintains a dedicated list of cleared or approved companion diagnostic devices, reflecting the growing role of these tests in selecting appropriate therapies.
Rising Integration of Liquid Biopsy and Advanced Genomic Testing
The companion diagnostics market is also moving toward less-invasive testing methods, particularly liquid biopsy and next-generation sequencing (NGS). These technologies can analyze tumor-related genetic material from blood samples and may help clinicians identify actionable mutations when obtaining tissue is difficult. The National Cancer Institute (NCI) continues to support research into circulating tumor DNA and other biomarkers for cancer detection, treatment selection, and monitoring.
Growing Adoption of Precision Medicine and Targeted Therapies
The companion diagnostics market growth is primarily driven by the increasing adoption of precision medicine and targeted therapies, particularly in oncology. Companion diagnostics help identify patients who are more likely to benefit from specific medicines, enabling physicians to make more informed treatment decisions and reduce exposure to ineffective therapies. Growing investments in biomarker discovery, molecular testing, next-generation sequencing, and personalized healthcare are accelerating market adoption. The companion diagnostics market growth is also supported by the expanding pipeline of targeted drugs, increasing use of genomic profiling, and regulatory emphasis on linking diagnostic tests with certain therapies. Rising demand for individualized treatment strategies is further strengthening clinical adoption.
High Development Costs and Complex Regulatory Requirements
The companion diagnostics market faces significant restraints due to the high cost and complexity of developing, validating, and commercializing diagnostic tests alongside targeted therapies. Diagnostic developers must demonstrate analytical performance, clinical validity, and clinical utility while coordinating development timelines with pharmaceutical companies. The companion diagnostics market analysis also indicates that differing regulatory requirements across countries can increase approval timelines and commercialization expenses. Limited availability of specialized laboratories, skilled molecular diagnosticians, and advanced testing infrastructure can restrict access in developing markets. Reimbursement uncertainty for biomarker testing also remains a barrier to broader clinical adoption.
Expansion of Biomarker Testing and Next-Generation Sequencing
The increasing use of molecular biomarkers and next-generation sequencing is creating significant opportunities for the companion diagnostics market. Pharmaceutical and diagnostic companies are increasingly collaborating to identify biomarkers that can support patient selection during clinical development and routine treatment. The companion diagnostics market analysis highlights growing applications in cancer immunotherapy, targeted oncology drugs, rare diseases, and emerging cell and gene therapies. Multiplex testing platforms can evaluate several biomarkers from a single sample, improving efficiency and supporting broader precision medicine strategies. Continued advances in liquid biopsy and genomic profiling are expected to create substantial long-term opportunities.
Ensuring Test Accuracy, Accessibility, and Treatment Compatibility
One of the major challenges facing the companion diagnostics market is maintaining high testing accuracy while ensuring that diagnostic results reliably support treatment decisions. Biomarker expression can vary between patients and may change during disease progression or treatment, requiring advanced testing and monitoring strategies. The companion diagnostics market growth is also affected by complex regulatory pathways, interoperability issues, reimbursement limitations, and the need to synchronize diagnostic availability with drug launches. Ensuring laboratories can consistently perform sophisticated tests across different healthcare settings remains challenging. Balancing clinical reliability, affordability, accessibility, and pharmaceutical-diagnostic coordination remains critical for sustained market development.
Request Customizationto receive a tailored report.
Polymerase Chain Reaction (PCR) Dominated the Market with 35.8% Share in 2025
The polymerase chain reaction (PCR) segment accounted for the largest share of the global companion diagnostics market at 35.8% in 2025, driven by its high sensitivity, established clinical utility, and widespread use in biomarker detection and patient stratification for targeted therapies.
Next-generation sequencing (NGS) is projected to register the fastest growth at a CAGR of 13.5% during 2026–2034, supported by increasing demand for comprehensive genomic profiling, advances in precision medicine, and the growing use of multi-biomarker testing. Immunohistochemistry remains an important technology for identifying protein biomarkers and guiding treatment decisions, while in situ hybridization continues to support molecular diagnostics by enabling the detection of specific genetic alterations. Other technologies also contribute to companion diagnostic testing across specialized clinical applications.
Oncology Dominated the Market with 66.8% Share in 2025
The oncology segment accounted for the largest share of the global companion diagnostics market at 66.8% in 2025, driven by the growing adoption of precision oncology, increasing cancer incidence, and the expanding availability of targeted therapies that require biomarker-based patient selection.
Autoimmune diseases continue to represent an important application area as companion diagnostics help identify patients who are more likely to respond to specific treatments. Cardiovascular diseases are increasingly incorporating molecular and genetic testing, while central nervous system disorders are benefiting from advances in biomarker identification and personalized medicine. Virology diseases also contribute to market growth through molecular testing and treatment-response assessment, while other indications continue to expand as precision medicine approaches become more widely adopted.
Speak to an Analystto discuss market opportunities.
North America accounted for a 42.5% companion diagnostics market share, valued at USD 3.82 billion in 2025. The region's growth is driven by increasing adoption of precision medicine, rising demand for biomarker-based testing, strong pharmaceutical and biotechnology research, and advanced healthcare infrastructure. Growing development of targeted therapies and increasing investments in oncology diagnostics continue to support regional companion diagnostics market growth.
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by increasing adoption of precision medicine, expanding use of molecular and biomarker testing, rising development of targeted therapies, and the presence of leading pharmaceutical, biotechnology, and diagnostic companies. Strong clinical research capabilities and regulatory support further strengthen the country's market position.
Canada market is witnessing steady market growth due to increasing adoption of personalized medicine, expanding molecular diagnostic capabilities, rising investments in cancer research, and growing demand for biomarker-based testing to support targeted therapies.
Europe market accounted for 27.4% of the global companion diagnostics market, reaching USD 2.46 billion in 2025. Market growth is supported by increasing adoption of precision medicine, rising demand for molecular diagnostics, expanding pharmaceutical research, and growing use of biomarker testing in oncology and other therapeutic areas. Strong healthcare infrastructure and increasing investments in personalized treatment continue to drive regional demand.
The United Kingdom market is witnessing steady market growth owing to increasing adoption of precision medicine, expanding genomic and molecular testing programmes, rising investments in cancer diagnostics, and growing integration of companion diagnostics into targeted treatment strategies.
Germany market represents one of the largest markets in Europe, driven by advanced healthcare infrastructure, increasing adoption of molecular diagnostics, strong pharmaceutical research capabilities, and growing demand for biomarker-based testing and personalized therapies.
Asia Pacific market accounted for 21.6% of the global companion diagnostics market, valued at USD 1.94 billion in 2025, and is projected to register the fastest CAGR of 13.4% during the forecast period. The market is expanding due to increasing healthcare expenditure, rising adoption of precision medicine, growing investments in biotechnology and molecular diagnostics, and improving access to advanced testing technologies. Expanding cancer diagnostics and targeted therapy applications continue to support regional market growth.
Japan market is witnessing steady market growth due to increasing adoption of precision medicine, expanding molecular diagnostic testing, growing investments in oncology research, and rising use of biomarker-based companion diagnostics for targeted therapies.
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by increasing healthcare investments, expanding molecular diagnostics infrastructure, rising adoption of precision oncology, and growing development of targeted therapies and biomarker-based testing.
The Middle East & Africa market represented 3.4% of the global companion diagnostics market, totaling USD 0.31 billion in 2025. Rising investments in healthcare infrastructure, increasing adoption of molecular diagnostics, growing awareness of precision medicine, and expanding access to advanced cancer testing are supporting regional market growth.
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare infrastructure, expanding adoption of precision medicine, growing availability of molecular diagnostic technologies, and government initiatives supporting personalized healthcare.
Africa market is witnessing gradual market growth, supported by improving diagnostic infrastructure, increasing awareness of precision medicine, expanding access to molecular testing, and growing investments in cancer diagnosis and treatment. Countries such as South Africa, Kenya, and Nigeria are creating long-term growth opportunities for market participants.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com